Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1376112 | 1.00 | APP (0.34) | APPMAPTSNCAEPHX2MEN1 | |
| SCHEMBL1376114 | 1.00 | APP (0.34) | APPMAPTSNCAEPHX2MEN1 | |
| SCHEMBL1376395 | 0.88 | APP (0.36) | APPMAPTSNCAEPHX2MEN1 | |
| SCHEMBL1376396 | 0.88 | APP (0.36) | APPMAPTSNCAEPHX2MEN1 | |
| SCHEMBL2082285 | 0.82 | APP (0.40) | APPMAPTSNCA | |
| SCHEMBL2082283 | 0.82 | APP (0.40) | APPMAPTSNCA | |
| SCHEMBL1375815 | 0.79 | APP (0.38) | APPMAPTSNCA | |
| SCHEMBL1375816 | 0.79 | APP (0.38) | APPMAPTSNCA | |
| SCHEMBL1376393 | 0.79 | APP (0.42) | APPMAPTSNCAMEN1KMT2A | |
| SCHEMBL1376394 | 0.79 | APP (0.42) | APPMAPTSNCAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4727579-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-7897615-B2 | e.g. 2-Cyano-3-hydroxy-N-isopropyl-N-(2-mercapto-benzothiazol-6-yl)-3-(4-trifluoromethyl-phenyl)-acrylamide; cardiovascular disorders, antidiabetic, anticarcinogenic, antiischemic agent; obesity, metabolic disorders | CHUGAI SCIYAKU KABUSHIKI KAISHA (JP) | 2011-03-01 | — | — | US | claimed |
| US-20080161358-A1 | Cyanoamide Compounds Useful as Malonyl-COA Decarboxylase Inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2008-07-03 | — | — | US | claimed |
| US-7285562-B2 | Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-10-23 | — | — | US | claimed |
| EP-1648564-B1 | CYANOAMIDE COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2007-10-17 | — | — | EP | claimed |
| JP-2007501233-A | — | — | 2007-01-25 | — | — | JP | claimed |
| EP-1648564-A1 | CYANOAMIDE COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-04-26 | — | — | EP | claimed |
| WO-2005011812-A1 | CYANOAMIDE COMPOUNDS USEFUL AS MALONYL-COA DECARBOXYLASE INHIBITHORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-10 | — | — | WO | claimed |
| US-20050026945-A1 | Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026945-A1 | Cyanoamide compounds useful as malonyl-CoA decarboxylase inhibitors | ACACA, ACACB, MCCC2 | APP 2169/4885MAPT 2998/4885SNCA 3771/4885 |
| US-20080161358-A1 | Cyanoamide Compounds Useful as Malonyl-COA Decarboxylase Inhibitors | ACACA, ACACB, MCCC2 | APP 2074/4885MAPT 2963/4885SNCA 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.